Abstract: The disclosure describes methods which substantially increase the stability of levothyroxine sodium. The use of antioxidants sufficient to inhibit oxidative degradation are used in the pharmaceutical composition of tablets, which include a therapeutically effective amount of levothyroxine sodium. Packaging systems, including high-density polyethylene (HDPE) bottles, child-resistant caps (CRC) of HDPE Bottles, and blister packs, incorporate antioxidants, oxygen scavengers and/or desiccants that are capable of establishing and maintaining arid and anaerobic conditions for packaging of Levothyroxine Sodium Tablets.

Abstract: The present invention discloses a means to improve stability, dissolution, and in vivo bioavailability of non-aqueous oral formulations containing natural or synthetic cannabinoid derivatives. In particular, this invention provides a non-aqueous cannabinoid formulation containing zero amount of water with one or more organic solvents, surfactants, co-surfactants, semi-polar solvents and mono-di glycerides. Upon administration, these formulations produce nano-sized cannabinoid liquid globules.

Abstract: This invention relates to pharmaceutical dosage forms for delivery of drugs susceptible to abuse, such as, for example, oxycodone and/or oxymorphone.

Abstract: The invention describes a blister packaging system, and method of making the system, capable of establishing and maintaining arid and anaerobic conditions for packaging pharmaceutical products that are sensitive to oxygen and/or moisture. The blister packaging system encompasses, for example, a scaffold of several interconnected cavities intended for product and one or more reservoirs comprising an oxygen scavenger and/or a desiccant. Furthermore, the concentration of the components is maintained at a level that prevents establishment of equilibrium conditions.